(1R,2R,3R,4S)-3-(propan-2-yl)bicyclo[2.2.1]heptan-2-amine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1R,2R,3R,4S)-3-(propan-2-yl)bicyclo[2.2.1]heptan-2-amine
• 英文别名: (1R,2R,3R,4S)-3-propan-2-ylbicyclo[2.2.1]heptan-2-amine
• 化学式: C₁₀H₁₉N
• 分子量: 153.26
• InChiKey: SHXVJSFOJHMEEQ-SGIHWFKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SULTAM DERIVATIVES
  申请人：Anderson Kevin W.

  公开号：US20110124686A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及符合式1的化合物，具有细胞毒活性。这些化合物可用于治疗癌症。
• [EN] AGENTS FOR REVERSING TOXIC PROTEINOPATHIES<br/>[FR] AGENTS POUR INVERSER DES PROTÉINOPATHIES TOXIQUES
  申请人：BROAD INST INC

  公开号：WO2020257736A1

  公开（公告）日：2020-12-24

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

  本公开涉及诊断和治疗或预防蛋白质病变的组合物和方法，特别是与MUC1相关的肾脏疾病（ADTKD-MUC1或MKD）、视网膜色素变性（例如由于视紫红质突变引起）、由UMOD突变引起的常染色体显性小管间质肾病（ADTKD-UMOD）以及由突变蛋白在内质网或其他分泌途径间室和/或囊泡中积累导致的其他形式的有毒蛋白病变等。本公开还确定并提供了TMED9结合剂，作为治疗或预防分泌途径蛋白病变的能力，并进一步提供了识别其他TMED9结合剂的方法。
• [EN] COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS À DES COMPOSÉS CONTENANT DE LA BICYCLO[2.2.1]HEPTANAMINE
  申请人：BROAD INST INC

  公开号：WO2022140654A1

  公开（公告）日：2022-06-30

  The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.

  本公开涉及含有双环[2.2.1]庚胺化合物及其盐的组合物和方法。
• Agents for reversing toxic proteinopathies
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US11207278B2

  公开（公告）日：2021-12-28

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

  本公开涉及用于诊断和治疗或预防蛋白病的组合物和方法，特别是MUC1相关性肾病（ADTKD-MUC1或MKD）、视网膜色素变性（例如，由于视网膜色素变性导致的视网膜色素变性）、由于UMOD突变导致的常染色体显性肾小管间质性肾病（ADTKD-UMOD）以及其他形式的毒性蛋白病、由于 UMOD 突变引起的常染色体显性肾小管间质性肾病（ADTKD-UMOD），以及由于突变蛋白在 ER 或其他分泌途径区室和/或囊泡中积累而导致的其他形式的毒性蛋白病等。本公开还确定并提供了能够治疗或预防分泌途径蛋白病的 TMED9 结合剂，并进一步提供了确定其他 TMED9 结合剂的方法。
• AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20210169827A1

  公开（公告）日：2021-06-10

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.